Abstract
Background and Aims: A subset of patients who undergo ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) will later be diagnosed with denovo Crohn’s disease (CD). These patients have a higher risk of pouch failure. In this study we evaluated inflammatory bowel disease (IBD) serology in patients with denovo CD and examined the success of anti-tumor necrosis factor-alpha (anti-TNFα) therapy in preventing ileostomy in denovo CD patients who failed anti-TNFα therapy prior to IPAA. Methods: A prospectively maintained database of patients undergoing IPAA was reviewed to identify patients who developed denovo CD (defined as small bowel inflammation above the pouch inlet or pouch fistula/perianal disease appearing more than 3 months after stoma closure). Clinical characteristics and IBD serology were analyzed. Treatment failure was defined as pouch failure requiring ileostomy or pouchectomy. Results: Of 350 patients included in the study, 92 (26%) patients developed denovo CD. Significantly more denovo CD patients had anti-I2 positivity post-operatively versus preoperatively (p=0.007). Anti-TNFα therapy successfully treated denovo CD in 28 out of 38 (74%) patients. Out of 17 patients with denovo CD who had failed to respond to anti-TNFα agents prior to surgery and were treated with anti-TNFα therapy after surgery, 12 (71%) patients responded to treatment. Conclusions: I2 serology may possibly help identify patients who have developed or are at risk for developing denovo CD. Anti-TNFα therapy for denovo CD after IPAA can help prevent permanent ileostomy in almost 75% of cases, even in patients who previously failed anti-TNFα treatment prior to surgery.

This publication has 31 references indexed in Scilit: